AR103428A1 - Anticuerpos de penetración celular - Google Patents
Anticuerpos de penetración celularInfo
- Publication number
- AR103428A1 AR103428A1 ARP160100103A ARP160100103A AR103428A1 AR 103428 A1 AR103428 A1 AR 103428A1 AR P160100103 A ARP160100103 A AR P160100103A AR P160100103 A ARP160100103 A AR P160100103A AR 103428 A1 AR103428 A1 AR 103428A1
- Authority
- AR
- Argentina
- Prior art keywords
- penetrate
- conjugates
- cell
- phosphorothioate
- antibodies
- Prior art date
Links
- 230000001413 cellular effect Effects 0.000 title 1
- 230000035515 penetration Effects 0.000 title 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 abstract 4
- 229960002685 biotin Drugs 0.000 abstract 2
- 235000020958 biotin Nutrition 0.000 abstract 2
- 239000011616 biotin Substances 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- -1 phosphorothioate nucleic acid Chemical group 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 abstract 2
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
- A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562104653P | 2015-01-16 | 2015-01-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103428A1 true AR103428A1 (es) | 2017-05-10 |
Family
ID=56406478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100103A AR103428A1 (es) | 2015-01-16 | 2016-01-15 | Anticuerpos de penetración celular |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11730789B2 (enExample) |
| EP (2) | EP3244910B1 (enExample) |
| JP (2) | JP7260248B2 (enExample) |
| KR (1) | KR20170098957A (enExample) |
| CN (2) | CN113797349A (enExample) |
| AR (1) | AR103428A1 (enExample) |
| AU (2) | AU2016206475B2 (enExample) |
| BR (1) | BR112017015203A2 (enExample) |
| CA (1) | CA2972986A1 (enExample) |
| EA (1) | EA201791610A1 (enExample) |
| IL (1) | IL253403A0 (enExample) |
| MX (2) | MX386621B (enExample) |
| PH (1) | PH12017501271A1 (enExample) |
| SG (1) | SG11201705413WA (enExample) |
| TW (1) | TW201632207A (enExample) |
| UY (1) | UY36519A (enExample) |
| WO (1) | WO2016115500A1 (enExample) |
| ZA (2) | ZA201705120B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2972986A1 (en) * | 2015-01-16 | 2016-07-21 | City Of Hope | Cell penetrating antibodies |
| EP3303635B1 (en) | 2015-06-01 | 2021-09-01 | California Institute of Technology | Compositions and methods for screening t cells with antigens for specific populations |
| US11661463B2 (en) | 2015-08-06 | 2023-05-30 | City Of Hope | Cell penetrating protein-antibody conjugates and methods of use |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| US12258613B2 (en) | 2017-03-08 | 2025-03-25 | California Institute Of Technology | Pairing antigen specificity of a T cell with T cell receptor sequences |
| WO2019014648A1 (en) * | 2017-07-13 | 2019-01-17 | City Of Hope | PEPTIDES CONJUGATED TO A PHOSPHOROTHIOATE AND METHODS OF USE |
| WO2019125033A1 (ko) * | 2017-12-22 | 2019-06-27 | (주)로피바이오 | 세포 내 침투능을 갖는 항 stat3 이중특이 항체 및 이를 포함하는 약학적 조성물 |
| KR102075724B1 (ko) | 2018-09-14 | 2020-02-10 | 한국원자력의학원 | 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도 |
| EP4146229A4 (en) * | 2020-05-05 | 2025-07-23 | Avidity Biosciences Inc | COMPOSITIONS AND METHODS FOR TREATING POMPE DISEASE |
| WO2022010539A1 (en) * | 2020-07-08 | 2022-01-13 | Octagon Therapeutics, Inc. | Cancer cell modulators |
| KR102739776B1 (ko) | 2020-10-26 | 2024-12-09 | 한국원자력의학원 | 로자탄을 유효성분으로 포함하는 항암제의 종양 침투력 증진용 조성물 및 이의 용도 |
| WO2024129459A1 (en) | 2022-12-16 | 2024-06-20 | University Of Rochester | Repairmen! of barrier dysfunction in esophagus |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| EP0495421B1 (en) | 1991-01-15 | 1996-08-21 | Alcon Laboratories, Inc. | Use of carrageenans in topical ophthalmic compositions |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| IL112372A (en) * | 1994-02-07 | 2001-08-26 | Res Dev Foundation | Non-viral vector for the delivery of genetic information to cells |
| DE19502912A1 (de) * | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilisierte Oligonucleotide |
| ATE477273T1 (de) | 1998-12-01 | 2010-08-15 | Facet Biotech Corp | Humanisierte antikoerper gegen gamma-interferon |
| WO2004005476A2 (en) * | 2002-07-03 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| WO2007025365A1 (en) * | 2005-08-31 | 2007-03-08 | Oncolytics Biotech Inc. | Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms |
| US8586708B2 (en) | 2005-10-28 | 2013-11-19 | Massachusetts Institute Of Technology | Monovalent streptavidin compositions |
| AU2006325030B2 (en) | 2005-12-16 | 2012-07-26 | Cellectis | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
| WO2009012356A2 (en) | 2007-07-17 | 2009-01-22 | The General Hospital Corporation | Imaging nucleic acid binding proteins |
| US20110218334A1 (en) | 2008-07-11 | 2011-09-08 | Alnylam Pharmaceuticals, Inc. | PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS |
| WO2010011346A1 (en) | 2008-07-24 | 2010-01-28 | Rxi Pharmaceuticals Corporation | Rnai constructs and uses therof |
| CA2922698C (en) * | 2013-08-29 | 2023-01-03 | City Of Hope | Cell penetrating conjugates comprising non-cell penetrating antibodies covalently attached to one or more phosphorothioate nucleic acids |
| CA2972986A1 (en) * | 2015-01-16 | 2016-07-21 | City Of Hope | Cell penetrating antibodies |
| CN114224907A (zh) * | 2015-07-02 | 2022-03-25 | 希望之城 | 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 |
| US20180243436A1 (en) * | 2015-08-06 | 2018-08-30 | City Of Hope | Therapeutic cell internalizing conjugates |
-
2016
- 2016-01-15 CA CA2972986A patent/CA2972986A1/en active Pending
- 2016-01-15 MX MX2017009272A patent/MX386621B/es unknown
- 2016-01-15 UY UY0001036519A patent/UY36519A/es unknown
- 2016-01-15 CN CN202111067358.2A patent/CN113797349A/zh active Pending
- 2016-01-15 BR BR112017015203A patent/BR112017015203A2/pt not_active Application Discontinuation
- 2016-01-15 KR KR1020177022702A patent/KR20170098957A/ko not_active Ceased
- 2016-01-15 EA EA201791610A patent/EA201791610A1/ru unknown
- 2016-01-15 EP EP16737990.8A patent/EP3244910B1/en active Active
- 2016-01-15 US US15/543,915 patent/US11730789B2/en active Active
- 2016-01-15 EP EP20190286.3A patent/EP3795168A1/en not_active Withdrawn
- 2016-01-15 SG SG11201705413WA patent/SG11201705413WA/en unknown
- 2016-01-15 WO PCT/US2016/013668 patent/WO2016115500A1/en not_active Ceased
- 2016-01-15 JP JP2017537397A patent/JP7260248B2/ja active Active
- 2016-01-15 TW TW105101220A patent/TW201632207A/zh unknown
- 2016-01-15 AR ARP160100103A patent/AR103428A1/es unknown
- 2016-01-15 AU AU2016206475A patent/AU2016206475B2/en active Active
- 2016-01-15 CN CN201680015852.5A patent/CN107427550B/zh active Active
-
2017
- 2017-07-10 IL IL253403A patent/IL253403A0/en unknown
- 2017-07-11 PH PH12017501271A patent/PH12017501271A1/en unknown
- 2017-07-14 MX MX2021011584A patent/MX2021011584A/es unknown
- 2017-07-27 ZA ZA2017/05120A patent/ZA201705120B/en unknown
-
2021
- 2021-05-25 JP JP2021087385A patent/JP2021152022A/ja active Pending
- 2021-07-23 ZA ZA2021/05220A patent/ZA202105220B/en unknown
-
2022
- 2022-01-30 AU AU2022200592A patent/AU2022200592A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180008667A1 (en) | 2018-01-11 |
| JP2018505870A (ja) | 2018-03-01 |
| CN113797349A (zh) | 2021-12-17 |
| US11730789B2 (en) | 2023-08-22 |
| EP3244910A1 (en) | 2017-11-22 |
| CA2972986A1 (en) | 2016-07-21 |
| EP3244910A4 (en) | 2018-08-08 |
| AU2022200592A1 (en) | 2022-02-24 |
| ZA202105220B (en) | 2023-01-25 |
| MX2021011584A (es) | 2021-10-13 |
| KR20170098957A (ko) | 2017-08-30 |
| AU2016206475A1 (en) | 2017-07-20 |
| CN107427550A (zh) | 2017-12-01 |
| MX2017009272A (es) | 2018-04-11 |
| BR112017015203A2 (pt) | 2018-03-13 |
| JP2021152022A (ja) | 2021-09-30 |
| UY36519A (es) | 2016-08-31 |
| JP7260248B2 (ja) | 2023-04-18 |
| CN107427550B (zh) | 2021-10-08 |
| PH12017501271A1 (en) | 2018-02-05 |
| IL253403A0 (en) | 2017-09-28 |
| EP3244910B1 (en) | 2020-09-16 |
| ZA201705120B (en) | 2022-02-23 |
| WO2016115500A1 (en) | 2016-07-21 |
| TW201632207A (zh) | 2016-09-16 |
| AU2016206475B2 (en) | 2021-11-04 |
| SG11201705413WA (en) | 2017-08-30 |
| EP3795168A1 (en) | 2021-03-24 |
| EA201791610A1 (ru) | 2017-12-29 |
| MX386621B (es) | 2025-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR103428A1 (es) | Anticuerpos de penetración celular | |
| MX2016002643A (es) | Conjugados de penetracion celular y metodos de uso de estos. | |
| BR112018071276A2 (pt) | anticorpos anti-il-33, composições, métodos e usos dos mesmos | |
| BR112019000970A2 (pt) | proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas | |
| BRPI0919473A2 (pt) | Agentes de ligação frizzled e usos dos mesmos | |
| IL269826A (en) | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same | |
| IL268888A (en) | Multispecific binding proteins targeting caix, ano1, mesothelin, trop2, cea, or claudin-18.2 | |
| BR112022009723A2 (pt) | Anticorpos específicos para cd47, pd-l1, e usos dos mesmos | |
| CR20180068A (es) | Constructos de anticuerpo para cd70 y cd3 | |
| AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| EA201700546A1 (ru) | Композит полипропилен - углеродное волокно | |
| CU23978B1 (es) | Composiciones para anticuerpos que se dirigen a la proteína de complemento c5 | |
| MX373280B (es) | Anticuerpos anti-egfrviii y usos de los mismos. | |
| CR20110496A (es) | Biespecificos anticuerpos anti-her | |
| EA201700547A1 (ru) | Армированная волокнами полимерная композиция | |
| MX2019004690A (es) | Constructos de anticuerpos. | |
| BR112013017947A2 (pt) | benzoazepinas substituídas como moduladores de receptor toll-like | |
| MX2016016980A (es) | Composiciones de asfalto para aplicaciones de techado, metodos para prepararlas, y material de asfalto con carga que las comprende. | |
| CO6351748A2 (es) | Anticuerpos contra il-6 y sus usos | |
| CR20170111A (es) | Derivados de benzodiazepina citotóxicos | |
| MX2019000641A (es) | Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso. | |
| EA201591454A1 (ru) | Связывающие внеклеточный матрикс синтетические пептидогликаны | |
| AR105642A1 (es) | Conjugados de proteína y anticuerpo para la penetración celular y métodos de uso | |
| BR112018067951A2 (pt) | moléculas que se ligam a ilt7 e métodos de uso destas | |
| MX2020013746A (es) | Metodos y composiciones para incrementar la produccion de arn bicatenario. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |